CN113081870A - Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics - Google Patents
Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics Download PDFInfo
- Publication number
- CN113081870A CN113081870A CN201911335640.7A CN201911335640A CN113081870A CN 113081870 A CN113081870 A CN 113081870A CN 201911335640 A CN201911335640 A CN 201911335640A CN 113081870 A CN113081870 A CN 113081870A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- oil
- nano
- polyglycerol
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 121
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 121
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 121
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 121
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 116
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 239000002502 liposome Substances 0.000 title description 11
- 150000002632 lipids Chemical class 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000002245 particle Substances 0.000 claims abstract description 39
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 12
- 239000007957 coemulsifier Substances 0.000 claims abstract description 10
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- 239000003921 oil Substances 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 14
- -1 jojoba oil Substances 0.000 claims description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 238000010008 shearing Methods 0.000 claims description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 2
- 240000007817 Olea europaea Species 0.000 claims description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- 229940071160 cocoate Drugs 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 229920001992 poloxamer 407 Polymers 0.000 claims description 2
- 229940044476 poloxamer 407 Drugs 0.000 claims description 2
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims description 2
- 229940066675 ricinoleate Drugs 0.000 claims description 2
- 229950011392 sorbitan stearate Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000011068 loading method Methods 0.000 abstract description 2
- 239000003960 organic solvent Substances 0.000 abstract description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000012071 phase Substances 0.000 description 20
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- 238000005303 weighing Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 229940078492 ppg-17 Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002088 nanocapsule Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000007709 nanocrystallization Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001749 carotenones Chemical class 0.000 description 1
- 235000005472 carotenones Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002064 nanoplatelet Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940094944 saccharide isomerate Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a preparation method of astaxanthin nano lipid particles and application of the astaxanthin nano lipid particles in cosmetics. The red and transparent astaxanthin nano lipid particle thick liquid with high astaxanthin content is prepared by loading the astaxanthin carrier with the astaxanthin, the oil, the emulsifier, the co-emulsifier, the water and the preservative, and the preparation process of the carrier does not contain organic solvents such as acetone, ethanol and the like, so that the red and transparent astaxanthin nano lipid particle thick liquid has good stability and water solubility, the preparation method is simple and controllable, the repeatability is good, and the obtained astaxanthin nano lipid particle has relatively stable property and can be widely applied to cosmetics containing the astaxanthin.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a high-content astaxanthin nano-lipid plasmid prepared by using astaxanthin oil as an active ingredient, a preparation method thereof and application of the astaxanthin nano-lipid plasmid in cosmetics.
Background
Astaxanthin (Astaxanthin) is purple crystal with molecular formula of C40H5204The relative molecular weight is 596.86, is fat-soluble ketocarotenoid, is a terpene unsaturated compound, and belongs to xanthophyll-beta-carotene family. Astaxanthin is the strongest natural antioxidant found in nature so far, and has the antioxidant capacity of 1000 times that of natural VE, 10 times that of beta-carotene, 17 times that of grape seed oil, 150 times that of anthocyanin OPC and 60 times that of coenzyme Q10. More and more research results show that the medicine can effectively eliminate free radicals in vivo and maintain the organismAstaxanthin has attracted much attention in the cosmetic field because of its body balance, slowing down skin aging and protecting skin health.
However, astaxanthin has poor solubility in water and is easily isomerized and degraded under light, oxygen, heat, acid and alkali conditions due to its high degree of unsaturation in the molecule, resulting in a number of limitations and challenges in the application development process, such as: (1) the natural astaxanthin extract is mainly oil, is insoluble in a system taking water as a solvent, has single dosage form and limited application range; (2) astaxanthin is unstable in property, is easy to be oxidized and degraded in the processing and storage processes, and is not beneficial to commodity production and storage; (3) astaxanthin has low bioavailability, serious resource waste and difficult achievement of effective absorption dosage, and various challenges greatly limit the application and popularization of astaxanthin. Therefore, how to change the form of the natural astaxanthin dosage form and how to improve the water dispersibility, stability and bioavailability of the natural astaxanthin becomes a key technical problem in the application and popularization process of the astaxanthin.
The nanometer lipid plasmid technology (NLC) is a passive targeting drug delivery technology which is developed on the basis of solid lipid plasmid (SLN) and has wide application. The nano lipid particle can select proper liquid and solid lipid to completely seal the active substance (medicine) in the lipid inner cavity, and the liquid lipid can change the regular lattice of the solid lipid to increase the proportion of irregular crystals in the nano lipid structure, increase the space capacity of the active substance and have higher coating content.
The nano-encapsulation technology can improve the solubility and stability of the astaxanthin in water and improve the compatibility of the astaxanthin in a formula. In the invention, the astaxanthin oil is prepared into the nano-liposome, so that the fishy smell of the astaxanthin can be reduced, the astaxanthin can be conveniently dissolved in water and conveniently applied in the field of cosmetics, and the astaxanthin can be favorably permeated into the deep layer of the skin to fully play the roles of oxidation resistance and aging resistance.
The patent about astaxanthin nanocrystallization disclosed by the Chinese intellectual property office mainly comprises the following steps: CN 104257632A, disclose an astaxanthin solid lipid nanoparticle and its preparation method, is prepared from lipid material and aqueous phase according to the mass ratio of 1:11, have provided the beneficial effects of increasing astaxanthin solubility and releasing medicine in vitro; CN 109985008A discloses a method for preparing astaxanthin solid self-microemulsion by physically mixing astaxanthin, grease, emulsifier, co-emulsifier and solid adsorbent for adsorption and preparing astaxanthin solid self-microemulsion at normal temperature; ③ CN 109381447A discloses astaxanthin phospholipid nanoparticles which are obtained by mixing an organic phase dissolved with high molecular polymer and astaxanthin and a water phase dissolved with phospholipid, ultrasonically emulsifying and volatilizing the organic phase and are used as inner ear medicaments; CN 106214501A discloses an astaxanthin lipid nanocapsule and a preparation method thereof, the components of the astaxanthin lipid nanocapsule comprise astaxanthin oil, phospholipid, dipropylene glycol, glycerol and deionized water, and the astaxanthin lipid nanocapsule with the particle size of less than 250nm is obtained by high-pressure homogenization treatment. CN 107307403A discloses a method for preparing a cold water dispersible astaxanthin micro-nano solid stable preparation by using a natural astaxanthin extract as a raw material through processes of low-temperature treatment, low-energy self-micro-emulsification, microencapsulation, drying, twice granulation embedding and the like; and CN 104042568A and CN 108403666A, which respectively disclose two preparation methods of astaxanthin microcapsules prepared by high-pressure microjet and freeze drying. The disclosed astaxanthin nanocrystallization preparation is mainly a solid system, does not use an organic solvent, does not use high-pressure microjet, and has good solubility and high-efficiency bioavailability.
Disclosure of Invention
The main purpose of the present invention is to provide an astaxanthin liposome and a preparation method thereof, so as to solve the problems of low solubility and poor stability of astaxanthin in water.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
an astaxanthin nano lipid plasmid comprises the following components in percentage by mass:
the astaxanthin raw material comprises esterified astaxanthin and free astaxanthin, and is extracted from the raw material by a solvent extraction method or a supercritical fluid extraction method, wherein the esterified astaxanthin comprises monoester and diester;
the base oil is one or more of squalane, coconut oil, corn oil, caprylic/capric triglyceride, grape seed oil, evening primrose oil, jojoba oil, olive oil, etc.;
the high astaxanthin-containing nano-lipid plasmid according to claim 1, wherein: the emulsifier is any one or more of Tween 60, Tween 80, Tween 20, polyglycerol-10 monolaurate, polyglycerol-6 caprylate, polyglycerol-10 stearate, sorbitan olive oleate, sorbitan stearate, olive oil PEG-7 esters, poloxamer 407, poloxamer 188, PEG-8 caprylic/capric glycerides, PEG-40 stearate and the like.
The high astaxanthin-containing nano-lipid plasmid according to claim 1, wherein: the coemulsifier is any one or combination of more than one of polyglycerol-3 cocoate, polyglycerol-3 diisostearate, PEG-30 dipolyhydroxystearate, cetyl PEG/PPG-10/1 dimethyl siloxane, polyglycerol-4 decanoate, cetostearyl alcohol, polyglycerol-6 ricinoleate, etc.
The humectant of claim 1 is any one or more of glycerin, butylene glycol, propylene glycol, dipropylene glycol, glyceryl polyether-7, glyceryl polyether-26, polyethylene glycol-400, glyceryl glucosyl polyether-20, etc.
The preservative according to claim 1 is one or more of phenoxyethanol, caprylyl glycol, ethylhexyl glycerin, p-hydroxyacetophenone, pentanediol, hexanediol, chlorphenesin, and the like.
The particle size range of the astaxanthin nano lipid particles is 20-200 nm;
the preparation method of the astaxanthin nano lipid plasmid comprises the following steps:
(1) preparing the following components in percentage by weight: 1-10% of astaxanthin, 1-20% of grease, 10-30% of emulsifier, 5-20% of co-emulsifier, 5-20% of humectant, 10-40% of water and 0-1% of preservative;
(2) stirring and dissolving the emulsifier and the co-emulsifier in a constant-temperature water bath at 50-80 ℃, and adding the mixture into an oil phase system for mixing;
(3) adding humectant, water and antiseptic at 50-80 deg.C, high-speed shearing to obtain astaxanthin primary emulsion, and homogenizing at 500-1000bar under high pressure for 1-5 times;
(4) stirring, cooling to normal temperature to obtain translucent to transparent orange red astaxanthin nano lipid particles
As an improvement of the invention, the preparation of the high-content astaxanthin nano lipid plasmid and the application thereof in cosmetics.
The carrier is loaded with astaxanthin, and the carrier has high astaxanthin loading amount.
The astaxanthin nano lipid particle has good stability and water solubility, the preparation method is simple and controllable, the repeatability is good, and the astaxanthin nano lipid particle can be applied to the preparation of cosmetics containing astaxanthin.
Compared with the prior art, the invention has the following beneficial effects because the technology is adopted:
(1) the astaxanthin nano lipid plasmid system has good stability;
(2) the astaxanthin-containing nano lipid plasmid has high astaxanthin load;
(3) the solubility of astaxanthin which is difficult to dissolve in water is improved, so that the bioavailability of the astaxanthin is improved;
(4) each component in the formula has high safety, no irritation to organisms and no toxicity, can be used as an intermediate type to be compounded with a cosmetic formula, has good compatibility, and can be widely used in the field of cosmetics;
drawings
FIG. 1 flow chart of preparation method of astaxanthin nano lipid plasmid
FIG. 2 particle size diagram of astaxanthin phospholipid nanoplatelets
Detailed Description
The present invention is further described below with reference to examples. These examples are intended to illustrate the invention and are not intended to limit the scope of the invention. The implementation conditions used in the examples can be further adjusted according to the conditions of the specific manufacturer.
Example 1:
weighing 0.1g of astaxanthin and 2.0g of corn oil, mixing the astaxanthin and the corn oil, and stirring at room temperature until most of the astaxanthin is dissolved in the corn oil to form an oil phase of a system; weighing 3g of Tween 80, 0.8g of cetyl PEG/PPG-10/1 dimethyl siloxane and 0.2g of cetostearyl alcohol, stirring in a constant-temperature water bath at 78 ℃, adding into the oil phase, and fully mixing to form a uniform phase; adding 1.8g of water, 2.0g of polyethylene glycol-400 and 0.1g of phenoxyethanol into the mixture of the oil phase, the emulsifier and the co-emulsifier in a constant-temperature water bath at 78 ℃, shearing at 5000rpm for 2min, and homogenizing at 800bar under high pressure for 3 times; and cooling to normal temperature to finally obtain the astaxanthin nano lipid particles.
Adding 1.0g of the astaxanthin nano lipid particle system into 100g of deionized water, uniformly dispersing, measuring by using a particle size analyzer that the average particle size of the astaxanthin nano lipid particle system after water dispersion is 61.2 +/-1.6 nm, standing at 25 ℃ for 1 month at room temperature, and then obtaining the astaxanthin nano lipid particle system with the average particle size of 70.7 +/-2.3 nm, wherein the particle size change has no obvious difference, and the stability is good.
Example 2:
weighing 2g of astaxanthin and 15g of squalane, mixing the astaxanthin and the squalane, stirring the astaxanthin and the squalane at room temperature, and dispersing and dissolving the astaxanthin into the squalane to form an oil phase of a system; weighing 30g of tween 20, 7g of polyglycerol polyricinoleate and 10g of polyglycerol-3 diisostearate, stirring in a constant-temperature water bath at 60 ℃, adding into the oil phase, and fully mixing to form a uniform phase; adding 10g glycerol, 25g water, 0.9g phenoxyethanol and 0.1g ethylhexyl glycerol into the mixture of oil phase, emulsifier and auxiliary emulsifier in a thermostatic water bath at 50 ℃, shearing at 3000rpm for 3min, and homogenizing at 600bar for 2 times; and cooling to normal temperature to finally obtain the astaxanthin nano lipid particles.
Adding 1.0g of astaxanthin liposome system into 100g of deionized water, uniformly dispersing, measuring by using a particle size analyzer that the average particle size of the astaxanthin liposome system after water dispersion is 67.5 +/-2.3 nm, standing at 25 ℃ for 1 month at room temperature, and then obtaining the astaxanthin liposome system with the average particle size of 74.7 +/-3.8 nm, wherein the particle size change has no obvious difference, and the stability is good.
Example 3:
weighing 0.5g of astaxanthin and 5.0g of caprylic/capric triglyceride, and mixing and stirring the astaxanthin and the caprylic/capric triglyceride uniformly to form an oil phase of a system; weighing 6.0g of polyglycerol-10 stearate, 1g of sorbitan olivetoleate and 2.5g of cetyl polyethylene glycol/polypropylene glycol-10/1 dimethyl siloxane, stirring in a constant temperature water bath at 50 ℃, adding into the oil phase, and fully mixing to form a uniform phase; adding 3.0g dipropylene glycol, 6.8g water and 0.2g phenoxyethanol into the mixture of the oil phase, the emulsifier and the co-emulsifier in a constant-temperature water bath at 50 ℃, shearing at 3500rpm for 1min, and homogenizing at 500bar for 1 time; and cooling to normal temperature to finally obtain the astaxanthin nano lipid particles.
Adding 1.0g of astaxanthin liposome system into 100g of deionized water, uniformly dispersing, measuring by using a particle size analyzer that the average particle size of the astaxanthin liposome system after water dispersion is 65.2 +/-3.1 nm, standing at 25 ℃ for 1 month at room temperature, and then the average particle size is 70.5 +/-2.4 nm, wherein the particle size change has no obvious difference, and the stability is good.
The astaxanthin nano lipid plasmid is applied to cosmetics, and the examples are as follows.
Example 1:
astaxanthin antioxidant essence
| Composition (I) | Mass percent (%) |
| Deionized water | 81.92 |
| EDTA-disodium salt | 0.05 |
| PEG/PPG-17/6 copolymer | 5 |
| Butanediol | 6.0 |
| Hyaluronic acid sodium salt | 0.05 |
| Hydroxyethyl cellulose | 0.18 |
| Astaxanthin nano lipid plasmid | 5 |
| Phenoxyethanol | 0.8 |
| Saccharide isomerate | 1 |
Accurately weighing deionized water (1% of the copolymer for dispersing astaxanthin nano lipid particles), EDTA-disodium, PEG/PPG-17/6 copolymer, butanediol, sodium hyaluronate and hydroxyethyl cellulose, stirring, mixing uniformly, heating to dissolve until the copolymer is transparent, adding the astaxanthin nano lipid particles dispersed uniformly by a small amount of deionized water in advance at 50 ℃, stirring uniformly, adding phenoxyethanol and saccharide isomerous body, cooling to room temperature, detecting and discharging.
Example 2:
astaxanthin antioxidation face mask
| Composition (I) | Mass percent (%) |
| Deionized water | 81.92 |
| EDTA-disodium salt | 0.05 |
| Polyacrylamide sodium salt | 0.1 |
| PEG/PPG-17/6 copolymer | 2 |
| Glycerol | 5.0 |
| Hyaluronic acid sodium salt | 0.02 |
| Hydroxyethyl cellulose | 0.03 |
| Astaxanthin nano lipid plasmid | 3 |
| P-hydroxyacetophenone | 0.4 |
| Pentanediol | 2 |
Accurately weighing deionized water (1% of which is reserved for dispersing astaxanthin nano lipid particles), EDTA-disodium, PEG/PPG-17/6 copolymer, glycerol, p-hydroxyacetophenone, sodium polyacrylate, sodium hyaluronate and hydroxyethyl cellulose, stirring, mixing uniformly, heating to dissolve until the mixture is transparent, adding the astaxanthin nano lipid particles which are dispersed uniformly by a small amount of deionized water in advance into the mixture at 50 ℃, stirring uniformly, adding pentanediol, cooling to room temperature, detecting and discharging qualified products.
Example 3:
astaxanthin antioxidation emulsion
Accurately weighing phase A, stirring, mixing uniformly, heating to 80-85 ℃ for uniform dissolution, heating phase B to 80-85 ℃ for complete dissolution, adding phase B into phase A, homogenizing at 3000rpm for 2-5min, stirring, cooling to 65 ℃, adding phase C, stirring uniformly, cooling to 45 ℃, adding astaxanthin nano lipid particles uniformly dispersed by a small amount of deionized water, stirring uniformly, adding phase E, stirring uniformly, cooling to room temperature, detecting, and discharging.
The above examples are only for illustrating the technical idea and features of the present invention, and the purpose of the present invention is to enable those skilled in the art to understand the content of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All changes, modifications, substitutions, combinations, and simplifications that may be made in accordance with the spirit of the invention are to be regarded as being equivalent and are intended to be included within the scope of the invention.
Claims (9)
1. An astaxanthin nano lipid plasmid is characterized by comprising the following components in percentage by mass:
2. the astaxanthin nanoliposome according to claim 1, wherein: the oil is one or more of squalane, coconut oil, corn oil, caprylic/capric triglyceride, grape seed oil, evening primrose oil, jojoba oil, and olive oil.
3. The high astaxanthin-containing nano-lipid plasmid according to claim 1, wherein: the emulsifier is any one or more of Tween 60, Tween 80, Tween 20, polyglycerol-10 monolaurate, polyglycerol-6 caprylate, polyglycerol-10 stearate, sorbitan olive oleate, sorbitan stearate, olive oil PEG-7 esters, poloxamer 407, poloxamer 188, PEG-8 caprylic/capric glycerides, PEG-40 stearate and the like.
4. The high astaxanthin-containing nano-lipid plasmid according to claim 1, wherein: the coemulsifier is any one or combination of more than one of polyglycerol-3 cocoate, polyglycerol-3 diisostearate, PEG-30 dipolyhydroxystearate, cetyl PEG/PPG-10/1 dimethyl siloxane, polyglycerol-4 decanoate, cetostearyl alcohol, polyglycerol-6 ricinoleate, etc.
5. The humectant of claim 1 is any one or more of glycerin, butylene glycol, propylene glycol, dipropylene glycol, glyceryl polyether-7, glyceryl polyether-26, polyethylene glycol-400, glyceryl glucosyl polyether-20, etc.
6. The preservative according to claim 1 is one or more of phenoxyethanol, caprylyl glycol, ethylhexyl glycerin, p-hydroxyacetophenone, pentanediol, hexanediol, chlorphenesin, and the like.
7. The astaxanthin nanoliposome according to claim 1, wherein: the particle size range of the astaxanthin nano lipid particle is 20-200 nm.
8. The astaxanthin nano-lipid plasmid according to claim 1, wherein the preparation method of the astaxanthin nano-lipid plasmid comprises the following steps:
(1) preparing the following components in percentage by weight: 1-10% of astaxanthin, 1-20% of grease, 10-30% of emulsifier, 5-20% of co-emulsifier, 5-20% of humectant, 10-40% of water and 0-1% of preservative;
(2) mixing astaxanthin and oil, and stirring at room temperature until the astaxanthin and the oil are dissolved to form an oil phase system;
(3) stirring and dissolving the emulsifier and the co-emulsifier in a constant-temperature water bath at 50-80 ℃, and adding the mixture into an oil phase system for mixing;
(4) adding humectant, water and antiseptic at 50-80 deg.C, high-speed shearing to obtain astaxanthin primary emulsion, and homogenizing at 500-1000bar under high pressure for 1-5 times;
(5) stirring, cooling to normal temperature to obtain translucent to transparent orange red astaxanthin nano lipid particles.
9. Use of an astaxanthin nano-lipoplast according to any one of claims 1 to 8 in cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911335640.7A CN113081870A (en) | 2019-12-23 | 2019-12-23 | Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911335640.7A CN113081870A (en) | 2019-12-23 | 2019-12-23 | Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113081870A true CN113081870A (en) | 2021-07-09 |
Family
ID=76663877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911335640.7A Withdrawn CN113081870A (en) | 2019-12-23 | 2019-12-23 | Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113081870A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114948772A (en) * | 2022-04-29 | 2022-08-30 | 可莱尼化妆品科技有限公司 | Astaxanthin nanocapsule and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104257632A (en) * | 2014-10-24 | 2015-01-07 | 北京化工大学 | Solid lipid nanometer particle for astaxanthin and preparation method of solid lipid nanometer particle |
| KR20190001950A (en) * | 2018-12-18 | 2019-01-07 | 주식회사 지디이 | Eye Drops Containing Astaxantin |
| CN109985008A (en) * | 2019-04-29 | 2019-07-09 | 东南大学 | A kind of astaxanthin Solid Self-microemulsion and preparation method thereof |
-
2019
- 2019-12-23 CN CN201911335640.7A patent/CN113081870A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104257632A (en) * | 2014-10-24 | 2015-01-07 | 北京化工大学 | Solid lipid nanometer particle for astaxanthin and preparation method of solid lipid nanometer particle |
| KR20190001950A (en) * | 2018-12-18 | 2019-01-07 | 주식회사 지디이 | Eye Drops Containing Astaxantin |
| CN109985008A (en) * | 2019-04-29 | 2019-07-09 | 东南大学 | A kind of astaxanthin Solid Self-microemulsion and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114948772A (en) * | 2022-04-29 | 2022-08-30 | 可莱尼化妆品科技有限公司 | Astaxanthin nanocapsule and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saez et al. | Lipid nanoparticles (SLN & NLC) for delivery of vitamin E: A comprehensive review | |
| Ganesan et al. | Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery | |
| Pardeike et al. | Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products | |
| Iqbal et al. | Nanostructured lipid carriers system: recent advances in drug delivery | |
| Gao et al. | Preparation and characterization of intravenously injectable curcumin nanosuspension | |
| Moribe et al. | Drug nanoparticle formulation using ascorbic acid derivatives | |
| CN101091890A (en) | Composite type emulsifier, and emulsion prepared by using the emulsifier, and preparation method | |
| Teeranachaideekul et al. | Influence of state and crystallinity of lipid matrix on physicochemical properties and permeation of capsaicin-loaded lipid nanoparticles for topical delivery | |
| de Souza Guedes et al. | An overview on topical administration of carotenoids and coenzyme Q10 loaded in lipid nanoparticles | |
| Kalariya et al. | Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications | |
| DE102008015366A1 (en) | Lyophilised nanoemulsion | |
| KR101521868B1 (en) | Preparation and stabilization of idebenone encapsulated with skin lipids complex and moisturizing oil and its application of anti-aging cosmetics | |
| CN107496186A (en) | A kind of Kaempferol nano-composition and its preparation method and application | |
| WO2022160970A1 (en) | Concentrated solution of insoluble drug not containing ethanol, and micellar solution prepared therefrom | |
| CN102688152A (en) | Composite anti-screening agent nanostructured lipid carrier and preparation method thereof | |
| CN110772482A (en) | Emulsion of high proportion emulsifier and preparation method thereof | |
| Geng et al. | Development and evaluation of astaxanthin as nanostructure lipid carriers in topical delivery | |
| WO2012146057A1 (en) | Curcuminoid injection solution and intravenous injection | |
| CN113081870A (en) | Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics | |
| CN102846552B (en) | Preparation and application of docetaxel lipid nanoparticle | |
| CN109481401A (en) | Acetylsalicylic acid and its derivative water-base nano emulsion formulation and preparation method thereof and its application | |
| JP5107553B2 (en) | Coenzyme Q10-containing cosmetic composition and cosmetics containing the same | |
| Shi et al. | Realgar nanoparticle-based microcapsules: preparation and in-vitro/in-vivo characterizations | |
| KR101975295B1 (en) | Nano particles composition and manufacturing method of 20(S)-protopanaxadiol(PPD) to improve dermal absorption | |
| CN115517988A (en) | Azelaic acid nano-lipid particle, freeze-dried powder, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information |
Address after: 314200 2nd floor, building 5, 988 Xinxing 2nd Road, Pinghu Economic and Technological Development Zone, Jiaxing City, Zhejiang Province Applicant after: Jiaxing ruifuli Biotechnology Co.,Ltd. Address before: 314200 2nd floor, building 5, 988 Xinxing 2nd Road, Pinghu Economic and Technological Development Zone, Jiaxing City, Zhejiang Province Applicant before: Jiaxing ruifuli Biotechnology Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 102, Building 10, No. 988 Xinxing Second Road, Zhongdai Street, Pinghu City, Jiaxing City, Zhejiang Province, 314200 Applicant after: Jiaxing ruifuli Biotechnology Co.,Ltd. Address before: 314200 2nd floor, building 5, 988 Xinxing 2nd Road, Pinghu Economic and Technological Development Zone, Jiaxing City, Zhejiang Province Applicant before: Jiaxing ruifuli Biotechnology Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210709 |
|
| WW01 | Invention patent application withdrawn after publication |